ArticleTranslational oncology2020
Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non-small-cell Lung Cancer.
Article in Translational oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Immune-cold NSCLC tumors harbor tumor-associated macrophages with elevated expression of immunoglobulin genes.Cancer immunology, immunotherapy : CII · 2026Article
- Article
- Immune checkpoints are predominantly co-expressed by clonally expanded CD4Journal of experimental & clinical cancer research : CR · 2023Article
- Location of CD39Journal for immunotherapy of cancer · 2023Article
- Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity.Nature immunology · 2023Article
- CD39Oncoimmunology · 2023Article
- Adenosine, Schizophrenia and Cancer: Does the Purinergic System Offer a Pathway to Treatment?International journal of molecular sciences · 2022Review
- The Purinergic Landscape of Non-Small Cell Lung Cancer.Cancers · 2022Review
- Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy.Frontiers in immunology · 2022Review
- Article
- Immune profiling identifies CD8Frontiers in immunology · 2022Article
- KSHV infection drives poorly cytotoxic CD56-negative natural killer cell differentiation in vivo upon KSHV/EBV dual infection.Cell reports · 2021Article
- Article
- Treg and Oligoclonal Expansion of Terminal Effector CD8Frontiers in immunology · 2021Review
- IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma.Cancer immunology, immunotherapy : CII · 2020Article
- New insights into the interaction of the immune system with non-small cell lung carcinomas.Translational lung cancer research · 2020Review
- CD39: the potential target in small cell lung cancer.Translational lung cancer research · 2020Article
- Targeting Immunometabolism Mediated by CD73 Pathway inFrontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer death in both sexes worldwide and has a predicted 5-year survival rate of <20%. Immunotherapy targeting immune checkpoints such as the programmed death 1 (PD-1) signaling pathway has led to a shift of paradigm in the treatment of advanced non-small-cell lung cancer (NSCLC) but remains without effect in ∼80% of patients. Accumulating evidence suggests that several immunosuppressive mechanisms may work together in NSCLC. The contribution and cooperation between different immunosuppressive mechanisms in NSCLC remain unknown. Recently, the CD39-adenosine pathway has gained increasing attention as a crucial immunosuppressive mechanism and possible target for immunotherapy. Immune cells were extracted from lung and tumor tissue after lung resection in 12 patients by combined enzymatic and mechanical tissue disaggregation. A multiparameter flow cytometry panel was established to investigate the expression and coexpression of CD39 and PD-1 on key lymphocyte subtypes. Frequencies of CD39
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.